SCHEMBL7703079

SCHEMBL7703079

C[C@H]1[C@H](NC(=O)c2ccc(Sc3cc(C#N)ccn3)cc2)C2CCN1CC2.C[C@H]1[C@H](NC(=O)c2ccc(Sc3cc(N4CCOCC4)ccn3)cc2)C2CCN1CC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.39
KDR P35968 1/20 0.37
JAK2 O60674 5/20 0.37
JAK3 P52333 5/20 0.37
CHRNA7 P36544 1/20 0.37
PPARG P37231 1/20 0.36
PLK4 O00444 6/20 0.36
JAK1 P23458 3/20 0.36
BMPR1B O00238 1/20 0.36
CIT O14578 1/20 0.36
GAK O14976 1/20 0.36
OPA1 O60313 1/20 0.36
ROCK2 O75116 1/20 0.36
STK16 O75716 1/20 0.36
PRKD3 O94806 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CDK2 P24941 1/20 0.36
MARK3 P27448 1/20 0.36
TYK2 P29597 1/20 0.36
BMPR1A P36894 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6879559 0.93 CHRNA7 (0.41) USP30CHRNA7PLK4HDAC1
SCHEMBL6881334 0.91 CHRNA7 (0.43) CHRNA7HCRTR2
SCHEMBL6883162 0.81 CHRNA7 (0.42) USP30CHRNA7PLK4HTT
SCHEMBL6883805 0.80 PIK3CA (0.45) USP30CHRNA7
SCHEMBL7705559 0.79 PPARG (0.38) USP30KDRJAK2JAK3PPARG
SCHEMBL6881381 0.78 CHRNA7 (0.45) CHRNA7
SCHEMBL6872641 0.78 USP30 (0.39) USP30CHRNA7
SCHEMBL6884099 0.78 CHRNA7 (0.46) USP30CHRNA7
SCHEMBL6882041 0.78 CHRNA7 (0.43) CHRNA7
SCHEMBL6880056 0.78 CHRNA7 (0.43) CHRNA7TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486172-B2 ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF BENZAMIDE OR BENZOCARBONYLSULFIDE SUBSTITUTED 1-AZABICYCLO(2,2,2)OCT-3-YL COMPOUNDS TO TREAT THE CONDITIONS ASSOCIATED WITH DEFECTS OF NICOTINIC SUBTYPES BRAIN RECEPTORS PHARMACIA & UPJOHN COMPANY 2002-11-26 US claimed